Igor Makhlin1, Kevin Fox2. 1. Division of Hematology & Oncology, Department of Medicine, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA. 2. Division of Hematology & Oncology, Department of Medicine, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA, USA. kevin.fox@pennmedicine.upenn.edu.
Abstract
PURPOSE OF REVIEW: Oligometastatic breast cancer (OMBC) remains a poorly understood entity for which no standard of care exists at this time. This review will focus on our biologic understanding of OMBC and provide an update on current treatment strategies. RECENT FINDINGS: The introduction of micro RNA expression profiling has advanced our understanding of the biologic underpinnings of OMBC. Although most of the data regarding treatment have come from retrospective studies, there are now prospective randomized trials reporting progression-free survival and overall survival improvements with stereotactic ablative radiotherapy (SABR). Ongoing studies designed to evaluate addition of SABR as well as other novel agents will further develop this field and provide new treatment options. A "cure" for OMBC remains elusive. With further basic research coupled with novel prospective trials, patients will hopefully enjoy increased progression-free survival and overall survival, and ideally a delay to more toxic systemic therapy.
PURPOSE OF REVIEW: Oligometastatic breast cancer (OMBC) remains a poorly understood entity for which no standard of care exists at this time. This review will focus on our biologic understanding of OMBC and provide an update on current treatment strategies. RECENT FINDINGS: The introduction of micro RNA expression profiling has advanced our understanding of the biologic underpinnings of OMBC. Although most of the data regarding treatment have come from retrospective studies, there are now prospective randomized trials reporting progression-free survival and overall survival improvements with stereotactic ablative radiotherapy (SABR). Ongoing studies designed to evaluate addition of SABR as well as other novel agents will further develop this field and provide new treatment options. A "cure" for OMBC remains elusive. With further basic research coupled with novel prospective trials, patients will hopefully enjoy increased progression-free survival and overall survival, and ideally a delay to more toxic systemic therapy.
Entities:
Keywords:
Oligometastatic breast cancer; Review oligometastatic breast cancer; SABR breast cancer
Authors: Robert C G Martin; Ken Robbins; Joan Falcó Fagés; Francisco Diaz Romero; Lisa Rustein; Dana Tomalty; Ricardo Monaco Journal: Breast Cancer Res Treat Date: 2011-12-27 Impact factor: 4.872
Authors: Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes Journal: N Engl J Med Date: 2017-11-09 Impact factor: 91.245
Authors: Marc D Piroth; David Krug; Petra Feyer; René Baumann; Stephanie Combs; Marciana-Nona Duma; Jürgen Dunst; Gerd Fastner; Rainer Fietkau; Matthias Guckenberger; Wulf Haase; Wolfgang Harms; Thomas Hehr; Felix Sedlmayer; Rainer Souchon; V Strnad; Wilfried Budach Journal: Strahlenther Onkol Date: 2022-05-08 Impact factor: 4.033